ABBOVE
8.9.2022 11:41:35 CEST | Business Wire | Press release
The Belgian solution provider Abbove, an emerging leader in the digital transformation of the wealth management industry, announces its partnership with Quintet Group’s Belgian branch Puilaetco to provide digital wealth planning services to their private banking clients. With the opportunity of expanding services to up to six new European countries, including the Netherlands, Denmark, Germany, and the United Kingdom, this marks another step for the company in spreading its wealth planning platform, if the Belgian pilot roll-out proves successful.
Currently, over 25,000 families in Europe received access to Abbove's platform via their trusted advisor. Starting today, Puilaetco's clients, who will use the technology under the name of “Richer Life Plan”, will expand that user base. By integrating the solution into their offer, the bank's advisors can now give their clients a global overview of their family's entire assets, as well as create simulations on the evolution of their wealth and the organization of their inheritance, all of this on a digital and 24/7 accessible platform.
“Since the beginning, it has been clear that our solution and vision are fully in tune with Quintet’s ambition. At Abbove, we develop a technology that helps financial institutions throughout the entire cycle of offering holistic wealth management services: from fully understanding a client’s global situation to delivering the best solutions based on his personal needs and guaranteeing a digital and interactive client experience. Not only our solution as such, but also our ambition to make our platform available internationally found a match with Quintet who have the will to spread the solution across their network in Europe after this first deployment in Belgium”, stated Guillaume Desclée, CEO and co-founder of Abbove.
Also commenting on the new partnership is Ludivine Pilate, Country CEO of Puilaetco: "With Richer Life Plan, we are entering a new era of customized wealth advice thanks to a complete and innovative technological solution. The tool perfectly matches our desire to strengthen the relationship of trust between our clients and our bankers: they share the same level of information, an indispensable basis for our experts to offer personalized solutions in terms of wealth structuring, investment, credit, or art advice.”
After opening up to banks across Europe at the beginning of June, this is the second private banking partnership announced by Abbove in three month’s time. The wealthtech’s solution is designed to help international banking groups add a digital and global layer to their wealth services so they can improve productivity, advice quality and user experience.
_____________________
About Abbove: Abbove SA is a Belgian WealthTech that develops a collaborative wealth planning platform for financial advisors and the families they accompany. Abbove’s technology helps financial advisors to digitize their wealth management services by improving the fluidity of internal processes and the client experience of the families they serve. The platform is currently distributed by 900 advisors to over 25,000 families in Europe. Visit www.abbove.com for more information.
About Puilaetco: With nearly 200 highly qualified employees and around ten billion euros of assets under management, Puilaetco, a Quintet Private Bank (Europe) S.A. Branch is a Belgian asset manager (founded in 1868) that offers its clients a personalized approach that is both innovative and traditional. As a trusted partner, the bank has been offering efficient, personalized and responsible solutions for five generations. These services include asset management, financial and estate planning, loans and artistic asset management.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005531/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom